Abstract
MicroRNAs (miRNAs) are small regulatory non-coding RNAs with a diversity of cellular functions, and are frequently dysregulated in cancer. Using a novel computational method (ActMir) that we recently developed, the “activity” of miRNA hsa-miR-500a was implicated in estrogen receptor (ER) positive breast cancer; however its targets and functional impact remain poorly understood. Here, we performed an extensive gene expression analysis in ER+ breast cancer cell lines, to reveal the targets of miR-500a-5p after experimental modulation of its levels. We found that among mRNAs targeted by miR-500a-5p there was enrichment in oxidative stress response genes. Moreover, in vitro exposure to oxidative stress using H2O2 induces miR-500a-5p overexpression and downregulation of the oxidative stress targets TXNRD1 and NFE2L2. Finally, expression of several of the identified miR-500a-5p targets related to oxidative stress, including TXNRD1, was associated with ER+ breast cancer survival in multiple datasets. Overall, we identify miR-500a-5p as an oxidative stress response miRNA whose activity may define breast cancer progression and survival.
Introduction
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression in physiological and pathological conditions by degradation of messenger RNAs (mRNAs) or translational inhibition1,2. The spatial and temporal balance between miRNAs and their targets is tightly controlled, and its dysregulation plays a critical role in cancer development and progression3. Despite their importance, knowledge of direct and indirect targets of miRNAs is still limited, partially due to the technical and bioinformatic complexity of analyzing multiple messenger RNAs (mRNAs) targeted by one single miRNA and the redundancy of miRNAs targeting the same mRNA. Adding to this complexity, the cellular context influences the activity of a specific miRNA and the pool of its functional targets.
Dysregulation of miRNAs has been extensively reported in breast cancer4,5, as well as their potential as prognostic and predictive biomarkers6. The conventional way of identifying key regulatory miRNA is through examination of miRNA-mRNA relationships based on expression levels; however, such association does not imply causal relationship and miRNA expression cannot be equated to functional “activity”. We recently developed a computational approach, ActMiR, for identifying active miRNAs and miRNA-mediated regulatory mechanisms. Leveraging the data from the Cancer Genome Atlas (TCGA) dataset, we identified let-7d and miR-18a to be key microRNAs and prognostic markers for estrogen receptor negative and human epidermal growth factor receptor 2 negative (ER−/HER2−) breast cancer7. These key miRNAs were functionally defined by the association between their activity and the expression levels of a number of genes, and their prognostic value for breast cancer survival was confirmed in an independent dataset. Using a similar approach, the “activity” of miR-500a was also implicated in ER+ breast cancer mortality7. Recently, miR-500a has been linked to gastric cancer development8. However, while the “activity” of a miRNA cannot be directly measured but only inferred by its target genes, a complete target screening is not available for miR-500a; such information would be useful for understanding the role of miR-500a in breast cancer progression and improving the design of breast cancer survival predictors.
Here, we aimed to identify functional targets of miR-500a in breast cancer cell lines as well as to assess the predictive value of its expression in different breast cancer cohorts. Our data points towards regulation of oxidative stress response as a major pathway by which miR-500a influences breast cancer progression.
Results and Discussion
miR-500a is variably expressed across human breast cell lines
Similar to other miRNAs, the miR-500a precursor (pre-miR-500a) is processed into miR-500a-5p (MIMAT0004773, guide strand) and miR-500a-3p (MIMAT0002871, passenger strand). However, few data are currently available to determine a priori which is the functional strand. Therefore, we measured the expression of both miR-500a strands in four different ER+ breast cancer cell lines (i.e. MCF-7, T47D, BT474, and ZR751) and two non-cancerous immortalized breast cell lines (i.e. MCF10A and hMEC). MiR-500a-5p and miR-500a-3p expression levels are quite heterogeneous across the different cell lines, with both strands being detectable in all cell lines (Fig. 1a). MCF-7 cells display the highest level of expression of both strands, while T47D cells showed the lowest. Therefore, to cover a wider range of biologically relevant targets, we decided to use these two well-known breast cancer cell lines to modulate miR-500a expression and further study its role in ER+ cancer cells. In addition, a recent report showed that miR-500a-5p promoted gastric cancer cell tumorigenicity and was associated with malignant progression and poor survival8. Based on this, we decided to focus on the guide strand for the next analyses.
Our experimental strategy comprised both, suppression and overexpression of miR-500a-5p. Therefore, we expected an effect in both, miR500a-High MCF-7 cells and miR500a-Low T47D cells. We experimentally modulated miR-500a-5p levels by transfecting cells with a miR-500a-5p mimic (for overexpression) or a miR-500a-5p inhibitor (for silencing). As a negative control, cells were transfected with miRCURY LNA negative control, a miRNA designed to lack targets in the human genome (see Methods). MCF-7 cells transfected with the mimic miRNA showed increased levels of miR-500a-5p of several thousand-fold compared to the control, while cells transfected with the inhibitor miRNA showed decreased levels of miR-500a-5p of 30-fold (Fig. 1b). The efficiency of induction and suppression of miR-500a-5p was similar to what was previously reported for miR-30a overexpression and silencing in the same cell line9. Transfection with mimic and inhibitor in T47D induced a 100-fold overexpression and a 100-fold silencing (Fig. 1b). In both cell lines, modulation of miR-500a-5p expression did not affect the expression of the passenger strand miR-500a-3p (Fig. 1b), indicating a high specificity of the mimic and miR-500a-5p inhibitor.
Our examination of cell phenotype following transfection with miR-500a-5p mimic or inhibitor showed that modulation of miR-500a-5p expression did not influence cell morphology, cell death rate, or cell proliferation (data not shown). However, overexpression of miR-500a was associated with an increased ability to grow in non-attachment conditions (i.e. mammospheres) in MCF-7 cells (Fig. 1c). Such conditions have been associated with “stemness” properties of breast cancer cells. Although a similar trend was observed in T47D, this difference was not significant. This can be explained, at least partially, by lower miR-500a levels in this cell line at basal and overexpression conditions.
Taken together, these results show that miR-500a is variably expressed in human breast cell lines, and that its modulation does not affect cell death or cell proliferation at short time points. An effect in the ability to grow under non-attachment conditions is observed in MCF-7 cells.
miR-500a-5p targets common transcripts in two breast cancer cell lines
Few studies have provided experimentally validated targets of miR-500a8, and no study is available in the context of breast cancer. Therefore, to identify the potential target genes of miR-500a in ER+ breast cancer cells, we adopted an unbiased approach by measuring whole transcriptome gene expression following modulation of miR-500a-5p levels by transfecting MCF-7 and T47D cells with miR-500a-5p mimic or miR-500a-5p inhibitor. After isolating RNA from each transfection condition (mimic, inhibitor or control miR) we interrogated gene expression using the Illumina HumanHT-12 v4 bead array, a technology that measures the expression of 31,000 annotated genes with more than 47,000 probes.
We next applied unsupervised clustering of the normalized expression data and found that expression profiles classify all samples according to the cell type (i.e. MCF-7 or T47D) (Fig. 2a). In addition, by plotting all samples according to the most variable probes (multidimensional scaling) we observed that within both cell lines there was a stronger effect of miRNA overexpression compared to miRNA inhibition (Figs 2b and S1). The divergent effect of mimics is more evident in MCF-7 cells, probably due to the higher efficiency of overexpression (several thousand-fold in MCF-7 vs. 100-fold in T47D).
To identify potential miR-500a-5p targets common to two ER+ breast cancer cell lines, we modeled the expression data as a function of cell type and experimental condition (see Methods). With this common design, we identified 413 differentially expressed transcripts between miR-500a-5p mimics and inhibitor (FDR-adjusted p value < 0.05) (Table S1). Most of these targets were downregulated after miR-500a-5p overexpression (n = 265), a fraction of which (n = 18) exhibited downregulation of more than two-fold (Fig. 2c and Table 1). Despite evident baseline differences between cell lines, the targets identified display a similar degree of downregulation relative to the non-treated conditions, in each case (Fig. 2c,d). Because of the global expression differences between both cell lines, we also performed separate analyses for each of them (Tables S2 and S3). Although more genes were differentially expressed in MCF-7 cells, there was a significant overlap between differentially expressed (DE) genes from both cell lines (eight times more than expected by chance, hypergeometric test p < 2.2 × 10−22) (Figs 2e and S1). The 36 common genes between both cell lines include those identified in the first analysis when using a fold-change threshold of at least two. For further discussion, we will refer only to the results of the combined analysis (modeling both cell types and all experimental conditions simultaneously) (Tables 1 and S1), as the robustness of the Bayesian approach applied here is known to benefit from including as many datasets as possible in the same analysis.
Table 1.
Symbol | Probe_Id | logFC | FDR | KM plotter | METABRIC | ||
---|---|---|---|---|---|---|---|
P value | HR | P value | HR | ||||
ABCC2 | ILMN_1676278 | −1.09 | 1.1E-02 | 2.10E-07 | 0.70 (0.61–0.80) | 0.115 | 1.33 (0.93–1.9) |
AKR1B10 | ILMN_1672148 | −1.71 | 7.0E-04 | 0.069 | 0.88 (0.77–1.01) | 0.001 | 1.59 (1.19–2.12) |
AKR1C2 | ILMN_2412336 | −2.71 | 6.1E-07 | 0.001 | 0.72 (0.59–0.87) | 0.032 | 0.8 (0.66–0.98) |
AKR1C3 | ILMN_1713124 | −2.56 | 2.0E-08 | 0.120 | 0.90 (0.78–1.03) | 0.031 | 0.81 (0.66–0.98) |
AKR1C4 | ILMN_1687757 | −2.78 | 1.5E-07 | 0.002 | 0.80 (0.69–0.92) | 0.007 | 0.76 (0.61–0.93) |
FAM129A | ILMN_1667966 | −1.02 | 2.0E-02 | 2.20E-13 | 0.62 (0.55–0.71) | 4.39E-03 | 0.72 (0.57–0.9) |
GPX2 | ILMN_2133205 | −1.32 | 6.3E-06 | 6.00E-03 | 0.82 (0.71–0.94) | 0.003 | 1.4 (1.12–1.75) |
HMOX1 | ILMN_1800512 | −1.13 | 6.0E-05 | 0.048 | 1.14 (1.00–1.29) | 0.004 | 1.5 (1.14–1.97) |
KIF18B | ILMN_1726682 | −1.41 | 1.8E-03 | 5.50E-11 | 1.53 (1.35–1.75) | 0.147 | 1.28 (0.92–1.79) |
LOC344887 | ILMN_3210914 | −1.25 | 3.1E-03 | 1.30E-09 | 0.56 (0.46–0.68) | NA | NA |
FTLP2 | ILMN_3288717 | −1.04 | 2.2E-06 | NA | NA | NA | NA |
HGD | ILMN_3239725 | −1.10 | 8.9E-07 | 0.003 | 1.23 (1.07–1.41) | 0.194 | 1.14 (0.94–1.38) |
PTGR1 | ILMN_1704531 | −1.17 | 5.5E-06 | 1.90E-06 | 0.63 (0.52–0.76) | 1.30E-04 | 0.7 (0.6–0.8) |
ILMN_2225537 | −1.09 | 8.9E-07 | |||||
SLC7A11 | ILMN_1655229 | −1.40 | 2.1E-05 | 0.074 | 0.89 (0.78–1.01) | 0.007 | 1.37 (1.09–1.72) |
TXNRD1 | ILMN_1717056 | −1.36 | 2.0E-08 | <1E-16 | 1.72 (1.52–1.96) | 1.12E-05 | 1.6 (1.3–1.9) |
ILMN_2324421 | −1.17 | 4.5E-06 | |||||
UGT1A6 | ILMN_1752813 | −1.06 | 3.7E-05 | 0.001 | 0.73 (0.60–0.88) | NA | NA |
We compared our list of 413 experimental miR-500a-5p targets (corresponding to 369 gene symbols) to a list of 315 predicted targets available at miRDB10. This webtool uses NCBI RefSeq sequences for identification of 3′-UTR sequences11, and target prediction with the MirTarget algorithm12. 38 genes overlapped between the two lists (six times more than expected by chance, hypergeometric test p value < 2.15 × 10−18) (Fig. 2f). Seven of the identified targets also overlapped with the original target list used to determine miR-500a activity7. A similar overlap was found with other algorithms for miRNA target prediction (Fig. S2).
Finally, we performed an in silico validation of our gene expression approach. To this end, we used the MiRonTop mining tool13 to infer the most enriched miRNAs in our expression dataset after miR500a-5p modulation (see Methods). For this particular analysis, we used the complementarity of the seed sequence to define a gene as a miRNA target, either in the UTRs (Fig. S2, left panel) or the coding sequence (CDS) (Fig. S2, right panel). Interestingly, miR500a-5p is significantly enriched only in the CDS targets. Importantly, miR500a-5p is the top most significant miRNA when taking together UTR and CDS targets. A similar result is obtained when using TargetScan14 as the reference dataset to define miRNA targets. In that case, miR500a-5p displays the highest enrichment among all human miRNAs.
We therefore identified 369 genes directly or indirectly targeted by miR-500a-5p in two ER+ breast cancer cell lines. Although these genes significantly overlap with predicted targets, many of them are described here for the first time. Our in silico validation gives strong support to our data. Moreover, they uncover a possible role of miR500a-5p in binding coding sequences for gene expression regulation. There is evidence for a biological role of miRNAs in such context15,16. A possible functional role, such as in splicing, could be an interesting guide for future research.
miR-500a-5p putative transcriptional targets are enriched in oxidative stress pathways
Because high miR-500a activity has recently been implicated as a key microRNA in ER+ breast cancer7, we next used the transcriptional targets described above in ER+ breast cancer cell lines to identify functional pathways that could explain such clinical observation. Gene set enrichment analyses showed that genes differentially down-regulated after miR-500a-5p overexpression were enriched in oxidative response pathways, and specifically in targets of NRF2 (Table 1 and Fig. S3). The transcription factor NRF2 [also known as NFE2L2, nuclear factor (erythroid-derived-2)-like 2] induces the transcription of several genes involved in the cellular antioxidant response, and is therefore considered as a major regulator of cell survival17. Interestingly, in our list of identified miR-500a-5p targets, the top most significant enrichments (all with FDR < 0.05) were found to be related to “Oxidative Stress Induced Gene Expression Via Nrf2” (BioCarta), “NRF2 pathway Homo sapiens” (WikiPathways), “NFE2L2 ChIP-Seq” (ChEA 2015), and “NFE2L2 CHEA” (ENCODE and ChEA Consensus TFs). Enrichment in oxidative stress genes was observed for all significant genes (FDR < 0.05), regardless of the fold-change filter (i.e. no filter, or two fold-change filter). Within the 18 transcripts (16 annotated genes) with more than two-fold change after miR-500a-5p overexpression, nine are known NRF2 targets (corresponding to seven annotated genes: SLC7A11, TXNRD1, GPX2, PTGR1, HMOX1, ABCC2, and UGT1A6) (Table 1). These results show that oxidative stress response genes are major targets of miR-500a-5p in ER+ breast cancer cell lines.
miR-500a-5p activity is modulated under oxidative stress conditions
We next aimed to characterize a functional effect of miR-500a in modulation of oxidative stress response. To this end, we exposed T47D and MCF-7 cells to different concentrations of the reactive oxygen species (ROS) hydrogen peroxide (H2O2) and monitored miR-500a-5p expression thereafter. Our results showed that non-lethal concentrations of H2O2 in both cell lines induced miR-500a-5p overexpression of more than two-fold (Fig. 3a). Of note, we used lower H2O2 concentrations in MCF-7 cells due to higher toxicity in this cell line (Fig. 3a and data not shown). Interestingly, the passenger strand miR-500a-3p was also overexpressed, although to a lower degree, in response to H2O2 treatment (Fig. 3a). Moreover, we also studied the expression of two of the oxidative stress targets of miR-500a-5p identified above, TXNRD1 and NFE2L2. In both cases, miR-500a-5p induction in response to H2O2 was associated with downregulation in both cell lines, although this was only significant in T47D cells (Fig. 3b).
These data suggest that miR-500a-5p does not only target oxidative stress response genes, but it is itself modulated under oxidative stress conditions.
miR-500a-5p target expression is associated with ER+ breast cancer survival
We examined associations between miR-500a-5p targets discovered above and ER+ breast cancer survival using multiple published datasets: METABRIC (n = 1852, 77% ER+)18 and combination of datasets provided by KM plotter19 (see Methods) (n = 2862, 72% ER+). We focused our analyses on the 16 miR-500a target genes with at least two fold-change in expression after miR-500a-5p modulation (Table 1). Consistent with previous findings of positive association between mortality and miR-500a activity7, many of miR-500 targets displayed inverse association with breast cancer mortality (i.e. hazard ratios (HRs) below one) (Table 1). Six miR-500 target genes were consistently associated with mortality in the two datasets (i.e. AKR1C4, AKR1C2, TXNRD1, PTGR1, HMOX1 and FAM129A) (Figs 4a and S4a). However, two of them, the oxidative stress genes TXNRD1 and HMOX1, were associated with increased mortality (HRs > 1). This is contrary to expectations for a direct miR-500a target, and suggests that dissociation between miR-500a-5p activity and degradation of some of its targets may be involved in breast cancer progression. Of note, this analysis also shows that the predictive power of several miR-500 targets is restricted to ER+ breast cancer (no significant association in ER− breast cancer subjects) (Figs 4b, S4 and S5), as expected from the reported specific association between miR-500a activity and ER+ breast cancer.
Large scale unbiased methods of miRNA target identification are a well-known strategy to uncover biological networks. In the present study, we performed a systematic identification of miR-500a targets. This miRNA is located in chromosome X, which is known to be heavily enriched in miRNA sequences (about 7% of miRNAs, or 113 miRNAs in total)20. Mir-500a is close to an estrogen receptor binding site, and within an intron of the chloride voltage-gated channel 5 (CLCN5) gene. It is clustered (within 10 kb) with hsa-mir-532, hsa-mir-188, hsa-mir-362, hsa-mir-501, hsa-mir-500b, hsa-mir-660, and hsa-mir-502 (miRDB). In addition to estrogen receptor, the expression of this whole cluster can be under the control of IL421 which is a cytokine linked to breast cancer metastasis22. Currently, only three genes which are negative regulators of NF-kB signaling (namely CYLD, TAX1BP1 and OTUD7B) have been discovered as validated targets for miR-500a in gastric cancer8. Of these, only TAX1BP1 was common to our target list (Table S1), a finding potentially explained by differences in cellular context. Overall, we show that miR-500a-5p controls the expression of multiple oxidative stress genes, and is itself overexpressed under oxidative stress conditions. Such targets include NFE2L2, a gene whose downregulation has been associated with poor outcome in breast cancer patients23. Among differentially oxidative stress targets we found Prostaglandin Reductase 1 (PTGR1) and Thioredoxin Reductase 1 (TXNRD1), one target predicted by in silico tools. Expression of these and five additional miR-500a targets identified here was able to independently predict overall breast cancer survival. This capacity of risk prediction was limited to ER+ breast cancers in five out of seven targets, in line with the described association between miR-500a activity and this subtype of breast cancers7.
Differential response to oxidation may represent a key factor in breast cancer prognosis. Alternatively, differences in oxidative stress could be the result of intrinsic characteristics of more aggressive tumors. In either case, our validated list of targets provides an insight into the potential role of miR-500a-5p in breast cancer survival.
Methods
Cell lines, cell culture conditions, and transfections
MCF-7, T47D, ZR751 cells (ER+ breast cancer cell lines), BT474 cells (ER+/HER2+ breast cancer cell lines) and hMEC and MCF10A cells (ER−, immortalized breast epithelial cells) were grown in standard (10% fetal calf serum, 1% penicillin/streptomycin, 1% sodium pyruvate and 1% glutamine) medium. Slightly attached cells from semi-confluent culture dishes were centrifuged and plated in mammosphere conditions, as previously described24. Refractive spheres of at least 10 cells (total diameter of approximately 50 μm) were considered as mammospheres. Alternatively, cells were counted and tested for viability with Trypan blue after trypsinization, and plated under non-attachment conditions with mammosphere medium.
In order to simulate oxidative stress conditions, we added H2O2 (Sigma Aldrich) to the media during one week. H2O2 100 mM was freshly prepared in PBS and then added to the media at final concentrations ranging from 0 to 100 uM.
hsa-miR-500a-5p sequence (miRCURY LNA™ microRNA mimic, Exiqon) and knock-down sequence (miRCURY LNA™ microRNA inhibitor) locked nucleic acid (LNA) (Exiqon) were used for overexpression and inhibition of miR-500a-5p, respectively. miRCURY LNA™ microRNA control (Exiqon) was used as negative (mock) control.
qRT-PCR
Extraction of total RNA, reverse transcription to cDNA and quantitative PCR (qPCR) were performed as previously described25. The miRNA fraction was collected separately from the total RNA. GAPDH was used as housekeeping gene in qPCR assays for gene expression, while SNORD44 was used as housekeeping miRNA.
Expression bead arrays
Total RNA was extracted using TRIzol (Sigma) according to the manufacturer’s instructions. For transcriptome analyses, total RNA from cells transfected with Pre-miR-500a-5p, miR-500a-5p inhibitor, or miRCURY LNATM microRNA control (Exiqon) was reverse-transcribed (Ambion Illumina Total Prep) and hybridized on HT12 Human bead chips (Illumina), as previously described9.
Raw expression data was imported and processed using R/Bioconductor packages26. Data quality was inspected using boxplots for the distribution of expression signals, and inter-sample relationship using multidimensional scaling plots and unsupervised clustering. To define differentially expressed (DE) genes, we modelled experimental condition (i.e. control, miR-500a-5p overexpression or inhibition) and cell type (i.e. MCF-7 or T47D) as categorical variables in a linear regression using an empirical Bayesian approach27. Comparisons with an FDR-adjusted P value below 0.05 were considered statistically significant. DE genes were further analyzed to determine functional pathways and ontology enrichment using EnrichR28,29 and DAVID30 web tools. miR-500a in silico predictions were obtained with the online database miRDB10. MiRonTOP13 was used for predictions of miRNA enrichment on the gene expression dataset (in silico validation) using the following parameters of significance: AVEEXP > 4, abs(LOGFC) > 0.15, and B > 0. All expression data have been deposited to the Gene Expression Omnibus repository (GEO accession number GSE92564).
Statistical analyses
R/Bioconductor packages were used for bead array analysis, as described above. For survival analyses the METABRIC dataset18 was downloaded from cBioPortal (www.cbioportal.org). Survival analysis was performed using the R package survival. For each gene, Cox survival model was built, using coxph() function for an interval of cutoff thresholds (from second to eighth decile) and the threshold with the lowest p-value was used (approach similar to the one used in31). Hazards ratio of high-vs-low expression and p-value were further used as main characteristics of the correlation of a given gene with survival. In addition, survival analysis was performed using the breast cancer dataset hosted at the KM plotter website19 (kmplot.com/analysis). This dataset contains expression data for 54,675 genes and survival information for 5143 breast cancer cases. For other comparisons, means and differences of the means with 95% confidence intervals were obtained using GraphPad Prism (GraphPad Software Inc.). Two-tailed student t test was used for unpaired analysis comparing average expression between classes. P values < 0.05 were considered statistically significant. Error bars in the graphs represent the standard deviation.
Electronic supplementary material
Acknowledgements
We thank Florence Le Calvez-Kelm and Geoffroy Durand from IARC’s Genetics Platform (GPS) for the processing and scanning of the Illumina HT12 arrays. This work was supported by the US National Institute of Health (NIH) R01 CA172460-1A1 (PI: Jia Chen, MicroRNA & Breast Cancer: Functional Characterization in a Population-Based Study) and U01 HG008451 (PI: Jun Zhu, Developing Methods for Curating Multi-Omics Data).
Author Contributions
D.D. and M.C. performed all miRNA experiments. V.A. performed the survival analyses. E.L. and J.Z. carried out the miR-500 activity analyses. J.C. and Z.H. provided conceptual assistance. J.C. and H.H. supervised the experiments and coordinated the project. D.D. and H.H. performed the statistical and bioinformatics analyses, and wrote the manuscript. All authors discussed the results and manuscript text.
Competing Interests
The authors declare that they have no competing interests.
Footnotes
Electronic supplementary material
Supplementary information accompanies this paper at 10.1038/s41598-017-16226-3.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Jia Chen, Email: jia.chen@mssm.edu.
Hector Hernandez-Vargas, Email: vargash@iarc.fr.
References
- 1.Baek D, et al. The impact of microRNAs on protein output. Nature. 2008;455:64–71. doi: 10.1038/nature07242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Selbach M, et al. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455:58–63. doi: 10.1038/nature07228. [DOI] [PubMed] [Google Scholar]
- 3.Hata, A. & Lieberman, J. Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci. Signal. 8 (2015). [DOI] [PubMed]
- 4.Dvinge H, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013;497:378–382. doi: 10.1038/nature12108. [DOI] [PubMed] [Google Scholar]
- 5.Network, C. G. A. Comprehensive molecular portraits of human breast tumours (2012). [DOI] [PMC free article] [PubMed]
- 6.van Schooneveld, E. et al. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. BCR17 (2015). [DOI] [PMC free article] [PubMed]
- 7.Lee E, et al. Inferred miRNA activity identifies miRNA-mediated regulatory networks underlying multiple cancers. Bioinforma. 2016;32:96–105. doi: 10.1093/bioinformatics/btv531. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Zhang L, et al. MicroRNA-500 sustains nuclear factor-κB activation and induces gastric cancer cell proliferation and resistance to apoptosis. Oncotarget. 2015;6:2483–2495. doi: 10.18632/oncotarget.2800. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Ouzounova, M. et al. MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells. BMC Genomic-14 (2013). [DOI] [PMC free article] [PubMed]
- 10.Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic acids Res. 2015;43:D146–D152. doi: 10.1093/nar/gku1104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.NCBI Resource Coordinators. Database resources of the National Center for Biotechnology Information. Nucleic acids Res. 42, D7-17 (2014). [DOI] [PMC free article] [PubMed]
- 12.Wang X, El Naqa IM. Prediction of both conserved and nonconserved microRNA targets in animals. Bioinforma. 2008;24:325–332. doi: 10.1093/bioinformatics/btm595. [DOI] [PubMed] [Google Scholar]
- 13.Le Brigand K, Robbe-Sermesant K, Mari B, Barbry P. MiRonTop: mining microRNAs targets across large scale gene expression studies. Bioinforma. 2010;26:3131–3132. doi: 10.1093/bioinformatics/btq589. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Agarwal, V., Bell, G. W., Nam, J.-W. & Bartel, D. P. Predicting effective microRNA target sites in mammalian mRNAs. eLife4 (2015). [DOI] [PMC free article] [PubMed]
- 15.Hausser J, Syed AP, Bilen B, Zavolan M. Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation. Genome Res. 2013;23:604–615. doi: 10.1101/gr.139758.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Spengler RM, et al. Elucidation of transcriptome-wide microRNA binding sites in human cardiac tissues by Ago2 HITS-CLIP. Nucleic acids Res. 2016;44:7120–7131. doi: 10.1093/nar/gkw640. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Menegon S, Columbano A, Giordano S. The Dual Roles of NRF2 in Cancer. Trends Mol. Med. 2016;22:578–593. doi: 10.1016/j.molmed.2016.05.002. [DOI] [PubMed] [Google Scholar]
- 18.Curtis C, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–352. doi: 10.1038/nature10983. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Györffy B, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 2010;123:725–731. doi: 10.1007/s10549-009-0674-9. [DOI] [PubMed] [Google Scholar]
- 20.Pinheiro I, Dejager L, Libert C. X-chromosome-located microRNAs in immunity: might they explain male/female differences? The X chromosome-genomic context may affect X-located miRNAs and downstream signaling, thereby contributing to the enhanced immune response of females. BioEssays: news Rev. Mol. Cell. Dev. Biol. 2011;33:791–802. doi: 10.1002/bies.201100047. [DOI] [PubMed] [Google Scholar]
- 21.Ruiz-Lafuente, N. et al. IL-4 Up-Regulates MiR-21 and the MiRNAs Hosted in the CLCN5 Gene in Chronic Lymphocytic Leukemia. PloS one10 (2015). [DOI] [PMC free article] [PubMed]
- 22.Venmar, K. T. & Fingleton, B. Lessons from immunology: IL4R directly promotes mammary tumor metastasis. Oncoimmunology3 (2014). [DOI] [PMC free article] [PubMed]
- 23.Wolf, B., Goebel, G., Hackl, H. & Fiegl, H. Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients. BMC Cancer16 (2016). [DOI] [PMC free article] [PubMed]
- 24.Hernandez-Vargas H, et al. Methylome analysis reveals Jak-STAT pathway deregulation in putative breast cancer stem cells. Epigenetics: Off. J. DNA Methylation Soc. 2011;6:428–439. doi: 10.4161/epi.6.4.14515. [DOI] [PubMed] [Google Scholar]
- 25.Esposti DD, et al. Identification of novel long non-coding RNAs deregulated in hepatocellular carcinoma using RNA-sequencing. Oncotarget. 2016;7:31862–31877. doi: 10.18632/oncotarget.7364. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Du P, Kibbe WA, Lin S. M. lumi: a pipeline for processing Illumina microarray . Bioinforma. 2008;24:1547–1548. doi: 10.1093/bioinformatics/btn224. [DOI] [PubMed] [Google Scholar]
- 27.Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical applications in genetics and molecular biology3 (2004). [DOI] [PubMed]
- 28.Kuleshov MV, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic acids Res. 2016;44:W90–W97. doi: 10.1093/nar/gkw377. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Chen EY, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinforma. 2013;14:128. doi: 10.1186/1471-2105-14-128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Huang DW, et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 2007;8:R183. doi: 10.1186/gb-2007-8-9-r183. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Mihály Z, et al. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. Breast Cancer Res. Treat. 2013;140:219–232. doi: 10.1007/s10549-013-2622-y. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.